Rongisch R, Koll P, Eming S A
Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Hautarzt. 2020 Nov;71(11):880-886. doi: 10.1007/s00105-020-04697-x.
The immune response is a central process during wound healing. Malfunctions often lead to chronic inflammation, barrier disorders, and ulcerations of the skin. The underlying pathomechanisms are complex and the subject of current dermatological research. The care of wound healing disorders is still inadequate and urgently needs improved therapy concepts. For several years now, the development of modern immunomodulators has enabled the targeted regulation of specific signaling cascades, and their effectiveness in the treatment of wound healing disorders has been proven in numerous case studies. Thus, their use not only leads to more efficient therapeutic approaches, but also provides deeper insight into the pathomechanistic importance of specific signaling pathways in inflammatory and degenerative diseases of the skin, which are poorly understood so far. Pyoderma gangrenosum, an autoinflammatory disease, provides a good example to illustrate the progress in therapy and pathomechanistic understanding through the use of new immunomodulators and is explained in more detail in the following article.
免疫反应是伤口愈合过程中的核心环节。功能失调常常导致慢性炎症、屏障紊乱以及皮肤溃疡。其潜在的发病机制复杂，是当前皮肤病学研究的课题。对伤口愈合障碍的护理仍然不足，迫切需要改进治疗理念。多年来，现代免疫调节剂的研发使得对特定信号级联反应进行靶向调控成为可能，并且它们在治疗伤口愈合障碍方面的有效性已在众多案例研究中得到证实。因此，它们的使用不仅带来了更有效的治疗方法，还让人们对特定信号通路在皮肤炎症性和退行性疾病中的发病机制重要性有了更深入的了解，而这些疾病目前仍了解甚少。坏疽性脓皮病是一种自身炎症性疾病，它为通过使用新型免疫调节剂说明治疗进展和发病机制理解提供了一个很好的例子，将在下文更详细地阐述。
